Latest news with #neuroplastogen
National Post
2 days ago
- Business
- National Post
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
Article content Article content Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen pipeline and IP platform. Q2 financial results were consistent with overall performance over the previous four quarters, and development costs were in line with budgeted IND-enabling activities. Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update. Article content CEO Commentary Article content 'The second quarter of 2025 represented a period of focused execution across all key areas of our business, most notably with the advancement of EB-003, our lead drug candidate,' said Joseph Tucker, Ph.D., Director and CEO of Enveric. 'We disclosed important new data demonstrating that EB-003 engages both the 5-HT₂ A and 5-HT₁ B receptors through a dual mechanism of action. We believe this receptor pairing forms the foundation for a novel pharmacological class. With this discovery, we believe EB-003 has emerged as a first-in-class therapeutic candidate with a dual mechanism that represents a unique therapeutic target with real-world clinical utility.' Article content 'This new pharmacological class is defined by agonism at the 5-HT₁ B receptor, which modulates affective tone, impulsivity, and reward pathways, as well as concurrent partial agonism at the 5-HT₂ A receptor, which supports cortical neuroplasticity. We believe this novel and unique profile has the potential to promote adaptive rewiring of brain circuits (i.e. neuroplasticity) while stabilizing emotional reactivity, motivational control, and behavioral regulation (i.e., generally psychological stability). It is expected to unlock the therapeutic benefits of serotonin mediated plasticity and guide those effects toward outcomes that are durable, broadly accessible, and clinically relevant for real-world patient populations.' Article content 'By targeting this specific set of neural receptors, the intent is for EB-003 to recalibrate emotional reactivity, facilitate extinction of maladaptive fear responses, and restore motivational tone. These are mechanisms believed to support lasting recovery in conditions such as post-traumatic stress disorder (PTSD), treatment resistant depression, and generalized anxiety. The addition of 5-HT₁ B agonism is intended to guide plasticity into emotionally grounded outcomes; thus, the designation of EB-003 as a first-in-class drug candidate.' Article content 'With these advances, EB-003 continues to differentiate itself in a competitive neuropsychiatric drug development landscape, with pre-IND test data for EB-003 pointing to a fast acting, durable, and non-hallucinogenic treatment for serious mental health conditions where currently available therapies are either too slow, poorly tolerated, or not very effective.' 'Beyond EB-003, we made meaningful progress in expanding our intellectual property portfolio, which remains a foundational pillar of our strategy. During the second quarter, we secured an additional patent grant in our EVM-301 portfolio and patent allowances across multiple distinct chemical classes in our EVM-301 and EVM-401 portfolios, further reinforcing Enveric's leadership in the discovery of rationally designed neuroplastogens. With a growing portfolio of issued patents and new filings underway, we are seeking to build a durable, competitive moat around our lead assets and future pipeline candidates.' Article content 'Looking ahead to the remainder of 2025 and into 2026, we remain sharply focused on filing an Investigational New Drug (IND) application for EB-003 and preparing for its first-in-human study. We also continue to benefit from ongoing dialogue and growing interest from established pharmaceutical companies with a strategic focus in neuropsychiatry, which underscores the increasing relevance of our platform in a field that has lacked innovation for far too long.' Article content Second Quarter and Recent Corporate Highlights Article content Revealed EB-003's Dual Mechanism of Action: Enveric confirmed that EB-003, its lead compound, engages both 5-HT₂ A (partial agonist) and 5-HT₁ B (agonist) receptors, a dual mechanism not previously reported in clinical-stage neuropsychiatric drug candidates. This unique pharmacology forms the basis of a new pharmacological class designed to promote therapeutic neuroplasticity, emotional recalibration, and enhanced control over affective and behavioral responses without the need for hallucinogenic intervention. Progressed Toward IND Submission: IND-enabling studies for EB-003 remain on track, with submission to the U.S. FDA anticipated in early 2026. Enveric continues to generate data supporting EB-003's safety, tolerability, and pharmacokinetic profile, including results supporting extended, repeat-dose oral use. Expanded Therapeutic Opportunity: PTSD: In a validated preclinical model, EB-003 produced rapid extinction of contextual fear responses following a single administration. Chronic Depression: Mice treated with EB-003 exhibited a statistically significant reduction in behavioral despair (p < 0.01) in the forced swim test, a standard model of antidepressant efficacy. Dosing Profile: Supporting data indicate EB-003 is well tolerated with daily oral administration, distinguishing it from hallucinogenic agents that require intensive supervision and infrequent dosing. Article content Intellectual Property Expansion Article content Broadened Patent Portfolio Across Two Molecular Classes: Filed a new patent application covering a novel chemical structure with potential relevance in neurodegenerative and cognitive indications. Received a Notice of Allowance from the U.S. Patent and Trademark Office for a second mescaline-derivative analogs patent, reinforcing Enveric's leadership in modifying classical psychedelic frameworks into non-hallucinogenic, drug-like structures. Secured a composition of matter patent on N-Substituted Tryptamine Derivatives, extending the Company's IP coverage of EVM-301 molecules into this new class of drugs and the serotonergic field. Article content Second Quarter 2025 Financial Results Article content Net loss attributable to common stockholders was $2.5 million for the quarter ending June 30, 2025, or $0.97 per share, compared to a net loss of $1.9 million, or $3.72 per share, for the same period in 2024. The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges. As of June 30, 2025, Enveric had cash and cash equivalents of $2.8 million. The Company continues to fund its operations through the use of various financing tools. The Company has raised net proceeds of $4.9M for the six months ended June 30, 2025. Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂ A and 5-HT₁ B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts Article content Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 dirish@ Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 cmcdonald@ Article content
National Post
16-06-2025
- Business
- National Post
Enveric Biosciences Announces Participation in 2025 BIO International Convention
Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. Article content During the conference, CEO and Director of Enveric, Joseph Tucker, Ph.D., will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and development strategy, recent corporate achievements, and anticipated milestones. Article content Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts Article content
Yahoo
11-06-2025
- Business
- Yahoo
Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
Rome, Italy, 11th June 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, announces its investment in Elkedonia SAS (Strasbourg, France), a pioneering biotech company developing a first-in-class neuroplastogen for the treatment of depression and other neuropsychiatric disorders. This €11.25 million seed round was co-led by Kurma Partners, WE Life Sciences and Bpifrance, with participation from Angelini Ventures, Argobio, Carma Fund, Capital Grand Est and Sambrinvest. The funds raised will be used to advance Elkedonia's novel neuroplastogen approach to identify and optimize drug-like small molecule inhibitors of Elk1, a novel intracellular target previously considered to be "undruggable". Elk1 plays a pivotal role in reward brain circuits and neuroplasticity. These mechanisms are often altered in conditions like depression, Post-Traumatic Stress Disorder (PTSD), and addiction, making them chronic instead of transient. Preclinical and clinical studies suggest that Elk1 inhibition offers a promising and differentiated new approach to treating treatment-resistant depression, with rapid efficacy and without the side effects of psychedelics or ketamine derivatives, such as sedation, dependence, or hallucinations. Part of the financing will be directed toward biomarker research and validation efforts, supporting a precision-based therapeutic strategy. This scientific and commercial potential was identified early by Argobio, which selected and developed Elkedonia within its venture studio. Founded in Paris and backed by leading investors including Angelini Ventures, Argobio partners with European academic institutions to transform early-stage discoveries into biotech companies, with a focus on rare diseases, neuroscience, oncology and is the first of these ventures to reach a significant financing milestone — a clear validation of Argobio's model and approach. This strong European investor syndicate reflects both the confidence of Argobio's founding investors in its model and Elkedonia's ability to attract leading life sciences investors at the seed stage. Building on this momentum, Argobio continues to expand its portfolio with the ambition to scale a repeatable model of biotech creation, driven by scientific excellence, entrepreneurial leadership and long-term investor alignment. 'We are excited to support Elkedonia's groundbreaking work in advancing neuroplastogens, which represents a potential first-in-class approach to treating depression,' said Fabrizio Calisti, Medical Director at Angelini Ventures. 'The novel nature of Elkedonia's target Elk1, previously thought to be undruggable, sets the company apart in the landscape of depression treatments, and we are proud to be part of this transformative journey. This investment reflects Angelini Ventures' commitment to supporting the exciting science coming out of European academic laboratories at the earliest stages via Argobio and subsequently providing further capital through our venture fund to accelerate the translation of cutting-edge research into therapies with the potential to transform outcomes for people with neuropsychiatric disorders.' Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Elkedonia's Board of Directors. 'I am thrilled to welcome our founding seed investors and thank my colleagues at Argobio for their support in creating Elkedonia. The novelty of our neuroplastogen approach offers a strong value proposition supported by groundbreaking neuroscience research. We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly,' said Delphine Charvin, Chief Executive Officer and Co-Founder of Elkedonia, previously Operating Partner at Argobio. 'In addition, our development of biomarkers will allow us to pursue a precision medicine for patient selection and treatment efficacy monitoring.' *** Notes to EditorsAbout Angelini Ventures Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested around €100 million into 21 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. About Angelini Industries Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over two billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it About Elkedonia Elkedonia is a Franco-Belgian start-up company dedicated to transforming the treatment of mental health disorders. Elkedonia is introducing a first-in-class antidepressant approach that leverages precision medicine. The lead discovery program targets the inhibition of the intracellular Elk1 protein to address the needs of treatment-resistant depression (TRD). About ArgobioArgobio is an international biotech start-up studio committed to turning cutting-edge innovations into breakthrough biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Seed or Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and ContactsAngelini VenturesMartina Palmese, Communications Media contacts for Italy - SEC Newgate ItaliaDaniele Pinosa, Tel. +39 3357233872Fausta Tagliarini; Tel. +39 3476474513Daniele Murgia; Tel. +39 3384330031 Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallowangeliniventures@
Yahoo
11-06-2025
- Business
- Yahoo
Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
Rome, Italy, 11th June 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, announces its investment in Elkedonia SAS (Strasbourg, France), a pioneering biotech company developing a first-in-class neuroplastogen for the treatment of depression and other neuropsychiatric disorders. This €11.25 million seed round was co-led by Kurma Partners, WE Life Sciences and Bpifrance, with participation from Angelini Ventures, Argobio, Carma Fund, Capital Grand Est and Sambrinvest. The funds raised will be used to advance Elkedonia's novel neuroplastogen approach to identify and optimize drug-like small molecule inhibitors of Elk1, a novel intracellular target previously considered to be "undruggable". Elk1 plays a pivotal role in reward brain circuits and neuroplasticity. These mechanisms are often altered in conditions like depression, Post-Traumatic Stress Disorder (PTSD), and addiction, making them chronic instead of transient. Preclinical and clinical studies suggest that Elk1 inhibition offers a promising and differentiated new approach to treating treatment-resistant depression, with rapid efficacy and without the side effects of psychedelics or ketamine derivatives, such as sedation, dependence, or hallucinations. Part of the financing will be directed toward biomarker research and validation efforts, supporting a precision-based therapeutic strategy. This scientific and commercial potential was identified early by Argobio, which selected and developed Elkedonia within its venture studio. Founded in Paris and backed by leading investors including Angelini Ventures, Argobio partners with European academic institutions to transform early-stage discoveries into biotech companies, with a focus on rare diseases, neuroscience, oncology and is the first of these ventures to reach a significant financing milestone — a clear validation of Argobio's model and approach. This strong European investor syndicate reflects both the confidence of Argobio's founding investors in its model and Elkedonia's ability to attract leading life sciences investors at the seed stage. Building on this momentum, Argobio continues to expand its portfolio with the ambition to scale a repeatable model of biotech creation, driven by scientific excellence, entrepreneurial leadership and long-term investor alignment. 'We are excited to support Elkedonia's groundbreaking work in advancing neuroplastogens, which represents a potential first-in-class approach to treating depression,' said Fabrizio Calisti, Medical Director at Angelini Ventures. 'The novel nature of Elkedonia's target Elk1, previously thought to be undruggable, sets the company apart in the landscape of depression treatments, and we are proud to be part of this transformative journey. This investment reflects Angelini Ventures' commitment to supporting the exciting science coming out of European academic laboratories at the earliest stages via Argobio and subsequently providing further capital through our venture fund to accelerate the translation of cutting-edge research into therapies with the potential to transform outcomes for people with neuropsychiatric disorders.' Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Elkedonia's Board of Directors. 'I am thrilled to welcome our founding seed investors and thank my colleagues at Argobio for their support in creating Elkedonia. The novelty of our neuroplastogen approach offers a strong value proposition supported by groundbreaking neuroscience research. We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly,' said Delphine Charvin, Chief Executive Officer and Co-Founder of Elkedonia, previously Operating Partner at Argobio. 'In addition, our development of biomarkers will allow us to pursue a precision medicine for patient selection and treatment efficacy monitoring.' *** Notes to EditorsAbout Angelini Ventures Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested around €100 million into 21 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. About Angelini Industries Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over two billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it About Elkedonia Elkedonia is a Franco-Belgian start-up company dedicated to transforming the treatment of mental health disorders. Elkedonia is introducing a first-in-class antidepressant approach that leverages precision medicine. The lead discovery program targets the inhibition of the intracellular Elk1 protein to address the needs of treatment-resistant depression (TRD). About ArgobioArgobio is an international biotech start-up studio committed to turning cutting-edge innovations into breakthrough biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Seed or Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and ContactsAngelini VenturesMartina Palmese, Communications Media contacts for Italy - SEC Newgate ItaliaDaniele Pinosa, Tel. +39 3357233872Fausta Tagliarini; Tel. +39 3476474513Daniele Murgia; Tel. +39 3384330031 Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallowangeliniventures@
Yahoo
11-06-2025
- Business
- Yahoo
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders
Delphine Charvin Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disorders First-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs such as ketamine Elkedonia, a new startup company launched by Argobio, attracts venture capital funding from a European syndicate of leading Life Sciences investors Elkedonia integrates research from Sorbonne University and industry experts from Argobio Delphine Charvin, transitioning from her role as Argobio Operating Partner, appointed as Elkedonia CEO Strasbourg, France and Charleroi, Belgium, June 11th 2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium. Elkedonia was founded by Argobio, an international startup studio whose mission is to launch and support translational research projects with disruptive therapeutic potential. The company leverages the translational research led by Dr Jocelyne Caboche, PhD, Director of Research at the National Center for Scientific Research (CNRS) at Sorbonne University. This research focuses on a novel intracellular target, Elk1, which plays a pivotal role in reward brain circuits and neuroplasticity – key mechanisms that are altered in conditions such as depression, post-traumatic stress disorder (PTSD) and addiction, making the conditions chronic instead of transient. Trauma, chronic stress, substance abuse and other factors can contribute to major depressive disorders and anhedonia (the inability to experience pleasure), driven by an impaired neuroplasticity. This disruption in the brain's ability to adapt leads to a breakdown in its normal functioning. Elkedonia is developing a neuroplastogen, to restore neuroplasticity without the side effects of psychedelics or ketamine derivatives. Supporting evidence from preclinical and clinical studies suggest that Elk1 inhibition is a therapeutic lever in depression, with rapid efficacy, and devoid of sedation, dependence, hallucinations or other side effects commonly associated with existing anti-depressant treatments. 'I am thrilled to welcome our founding seed investors and thank my colleagues at Argobio for their support in creating Elkedonia. The novelty of our neuroplastogen approach offers a strong value proposition supported by groundbreaking neuroscience research. We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly,' said Delphine Charvin, Chief Executive Officer and Co-Founder of Elkedonia, previously Operating Partner at Argobio. 'In addition, our development of biomarkers will allow us to pursue a precision medicine for patient selection and treatment efficacy monitoring.' 'Major depressive disorder is a large market of 300 million people globally that remains poorly addressed, with roughly one third of patients resistant to currently available treatments,' said Thierry Laugel, Chairman of the Management Board of Argobio and Managing Partner at Kurma Partners. 'Elkedonia serves as a first proof of concept for Argobio where we are extremely proud to have identified this opportunity to benefit human health and to have provided industry competencies to accelerate and de-risk product development. Furthermore, this seed investment co-led by our team at Kurma Partners is both an exciting opportunity for Kurma Biofund IV and builds on our overarching strategy of supporting creation of globally competitive companies across Europe.' 'Investing in Elkedonia demonstrates WE Life Sciences' commitment to advancing the best cutting-edge innovations through collaboration with top-tier European life sciences investors,' said Valentin Tonnel, Investment Director at WE Life Sciences. 'We are proud to support the realization of this promising innovation from Argobio, while fostering its growth in Wallonia, Belgium, a region increasingly recognized for its excellence in health and biotechnology.' 'Bpifrance, as a founding investor of Argobio, is delighted to support the seed round of this promising new venture,' said Jean-François Morin, Investment Director Life Sciences at Bpifrance. 'We are thrilled to develop the foundational research that comes from CNRS at Sorbonne University. This investment underscores our commitment to advancing mental health solutions, which is currently a priority for France.' Proceeds from the Seed financing will go toward identification and optimization of drug-like small molecule inhibitors of Elk1. Part of the financing will be directed toward biomarker research and validation efforts, supporting a precision-based therapeutic strategy. Major Depressive Disorder (MDD) is a fast growing and devastating health crisis, despite widely marketed anti-depressant therapeutics. Affecting around 25 million individuals in the United States, same numbers in Europe, and 300 million people worldwide, MDD is highly linked to a risk of suicide, that is the third leading cause of death among 15-29 year-olds. One third of patients affected by MDD do not respond to existing treatments, leading to the growing issue of treatment-resistant depression (TRD). This highlights the urgent need for innovative, effective and well tolerated solutions to address the unmet needs of those still suffering from this debilitating condition. Elkedonia ( is a Franco-Belgian start-up company dedicated to transforming the treatment of mental health disorders. Elkedonia is introducing a first-in-class antidepressant approach that leverages precision medicine. The lead discovery program targets the inhibition of the intracellular Elk1 protein to address the needs of treatment-resistant depression (TRD). Argobio ( is an international biotech start-up studio committed to turning cutting-edge innovations into breakthrough biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Seed or Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development. Kurma Partners ( Founded in Paris in 2009, Kurma Partners has become a key player in financing innovation to build the healthcare industry of tomorrow. Kurma invests in companies from their inception and to finance their growth, across the spectrum of the healthcare sector through its various franchises. These have grown with successive funds in early-stage biotechnology (Biofunds I, II, III and IV), digital health and early-stage diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and, more recently, growth capital (Kurma Growth Opportunities Fund). Kurma's teams, with a total of 25 people and 10 partners, are based in two offices, in Paris and Munich. They are deeply involved in the European ecosystem and have built up a solid network of international connections with prestigious research institutes, hospitals, entrepreneurs, industry and fellow investors. Kurma Partners is part of the Eurazeo group. WE Life Sciences ( ) is a public backed venture capital fund specialized in Life Sciences and based in Wallonia, Belgium. WE Life Scienes is committed to empowering breakthrough health innovations by supporting visionary researchers and entrepreneurs—the 'Local Heroes'—who turn scientific excellence into real-world solutions that improve lives. More than just investors, WE Life Sciences is a long-term partner. Its team brings deep sector expertise, strategic guidance, and international connectivity to help ventures grow from early-stage development to large-scale impact. By championing bold, high-potential companies across all stages, WE Life Sciences accelerates the emergence of next-generation health technologies—while helping position Wallonia as a vibrant, globally connected hub for life sciences. Bpifrance ( is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export…). Endowed with 500 million euros, the French Tech Seed Fund aims to support fundraising efforts of startups and innovative small businesses less than 3 years old that are developing highly technology-intensive innovations. As part of the 'Programme d'investissements d'avenir' (PIA), now part of France 2030, and operated on behalf of the French government by Bpifrance and operated by Bpifrance, the fund relies on certified business contributors who are responsible for identifying and qualifying these young companies and connecting them with private investors. Angelini Ventures ( the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested around €100 million into 18 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. CARMA FUND I ( is an early-stage investment fund for advancing Life Science and Healthcare technologies. The fund started off with a First Closing in June 2022 and has €50M under management. The Fund, based in Munich and Frankfurt am Main is uniquely suited for young companies and projects from the Life Science and medical space due to an extra-long term, flexible investment modes and its close relationships with leading technology transfer offices and industry partners. Capital Grand Est ( is an independent and AMF-approved regional private equity firm. Since 2012, the team of 14 professionals at Capital Grand Est has supported over 60 companies in the Grand Est and Bourgogne-Franche-Comté nearly €220 million in assets under management and 6 investment vehicles, Capital Grand Est structures capital operations for various types of businesses in the region to accelerate their success. Capital Grand Est supports all stages of business development: seed funding for innovative startups, expansion capital to accelerate growth, buyout operations to support shareholding evolutions, and rebound capital to assist companies in stabilizing their transition strategy. Sambrinvest ( with over 40 years of experience supporting businesses and entrepreneurs, a portfolio of nearly 330 SMEs, and more than €220 million under management, Sambrinvest is a key player in venture capital financing within the Charleroi region of Belgium. Beyond investing, Sambrinvest actively drives ecousystem growth, prioritizing strategic investments in companies within key sectors, namely industry, agrifood, materials, and life sciences. These efforts are further enhanced by major real estate investments, creating a fertile environment for business development. For more information please contact: Elkedonia Cohesion Bureau Delphine CharvinChief Executive International media & investorsChris Maggos +41 79 367 6254 French/Belgian mediaSophie Baumont 6 27 74 74 49 Attachments Delphine Charvin 2025-06-11_Elkedonia seed financing_final_ENError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
